Mirum Pharmaceuticals (NASDAQ:MIRM) Hits New 12-Month High Following Analyst Upgrade

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) reached a new 52-week high on Tuesday after HC Wainwright raised their price target on the stock from $102.00 to $130.00. HC Wainwright currently has a buy rating on the stock. Mirum Pharmaceuticals traded as high as $98.49 and last traded at $96.92, with a volume of 882340 shares. The stock had previously closed at $94.29.

Other analysts have also recently issued reports about the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $130.00 target price on shares of Mirum Pharmaceuticals in a research note on Monday, December 8th. Stifel Nicolaus lifted their price target on shares of Mirum Pharmaceuticals from $92.00 to $98.00 and gave the company a “buy” rating in a research note on Tuesday, December 16th. Raymond James Financial restated a “strong-buy” rating and set a $110.00 price objective on shares of Mirum Pharmaceuticals in a research report on Thursday, December 11th. Citigroup reaffirmed an “outperform” rating on shares of Mirum Pharmaceuticals in a report on Friday, December 19th. Finally, Evercore ISI reiterated an “outperform” rating and issued a $101.00 target price on shares of Mirum Pharmaceuticals in a research report on Tuesday, January 20th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $104.92.

Insider Buying and Selling

In other news, COO Peter Radovich sold 3,143 shares of the stock in a transaction dated Monday, January 26th. The shares were sold at an average price of $96.19, for a total value of $302,325.17. Following the completion of the sale, the chief operating officer directly owned 23,286 shares in the company, valued at $2,239,880.34. This represents a 11.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Eric Bjerkholt sold 1,421 shares of the business’s stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $93.33, for a total transaction of $132,621.93. Following the transaction, the chief financial officer owned 42,127 shares in the company, valued at $3,931,712.91. The trade was a 3.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 32,429 shares of company stock worth $3,039,396 in the last ninety days. Company insiders own 22.87% of the company’s stock.

Mirum Pharmaceuticals News Summary

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Director Patrick J. Heron bought 131,425 shares at $68.48 (~$9.0M), increasing his stake ~40% — a strong insider vote of confidence that typically supports share demand. Heron Form 4
• Positive Sentiment: HC Wainwright reiterated a Buy and raised its price target (reported lift to $130) while publishing bullish long‑term EPS projections (notably aggressive FY2030 and FY2029 estimates), which supports higher valuation expectations and likely attracted momentum buyers. Analyst Upgrade / 52‑Week High
• Positive Sentiment: Mirum completed its acquisition of Bluejay Therapeutics, expanding its rare‑disease pipeline and potential future revenue streams — a strategic corporate development investors view as accretive. Acquisition Announcement
• Neutral Sentiment: HC Wainwright adjusted near‑term EPS forecasts (cut FY2027 and trimmed FY2028 modestly) while raising longer‑range estimates — mixed guidance that tempers but does not negate the bullish long‑term thesis. HC Wainwright Estimates
• Negative Sentiment: Several senior executives sold stock on Jan 26 at about $96.19: CEO Christopher Peetz (6,831 shares, ≈$657K), COO Peter Radovich (3,143 shares), CFO Eric Bjerkholt (1,053 shares), and SVP Jolanda Howe (842 shares). Multiple insider sales on the same day can raise near‑term investor caution about insider liquidity needs despite the large director buy. CEO Form 4 COO Form 4 CFO Form 4 SVP Form 4

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. MCF Advisors LLC increased its holdings in shares of Mirum Pharmaceuticals by 76.4% in the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock valued at $31,000 after purchasing an additional 185 shares during the last quarter. Quantbot Technologies LP purchased a new stake in Mirum Pharmaceuticals in the 3rd quarter valued at $33,000. Comerica Bank increased its stake in shares of Mirum Pharmaceuticals by 45.1% in the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after acquiring an additional 278 shares during the last quarter. Quarry LP acquired a new stake in shares of Mirum Pharmaceuticals in the 3rd quarter worth $41,000. Finally, CWM LLC raised its holdings in shares of Mirum Pharmaceuticals by 30.8% during the 3rd quarter. CWM LLC now owns 683 shares of the company’s stock worth $50,000 after acquiring an additional 161 shares during the period.

Mirum Pharmaceuticals Stock Performance

The company has a debt-to-equity ratio of 1.06, a quick ratio of 3.16 and a current ratio of 3.31. The firm’s 50-day moving average price is $78.97 and its two-hundred day moving average price is $71.75. The stock has a market cap of $5.18 billion, a price-to-earnings ratio of -117.27 and a beta of 0.48.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.15. The firm had revenue of $133.01 million during the quarter, compared to analysts’ expectations of $130.11 million. Mirum Pharmaceuticals had a negative net margin of 8.78% and a negative return on equity of 16.47%. Mirum Pharmaceuticals’s revenue was up 47.1% compared to the same quarter last year. During the same period last year, the business earned ($0.30) earnings per share. On average, analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.